0000899243-22-021350.txt : 20220607 0000899243-22-021350.hdr.sgml : 20220607 20220607163705 ACCESSION NUMBER: 0000899243-22-021350 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220603 FILED AS OF DATE: 20220607 DATE AS OF CHANGE: 20220607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Vantage I, L.P. CENTRAL INDEX KEY: 0001765253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 221001616 BUSINESS ADDRESS: STREET 1: ONE SANSOME, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER NAME: FORMER CONFORMED NAME: Versant Opportunity Fund I, L.P. DATE OF NAME CHANGE: 20190117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Vantage I GP, L.P. CENTRAL INDEX KEY: 0001777651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 221001615 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Vantage I GP-GP, LLC CENTRAL INDEX KEY: 0001777653 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 221001614 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-03 1 0001808158 Repare Therapeutics Inc. RPTX 0001765253 Versant Vantage I, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001777651 Versant Vantage I GP, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001777653 Versant Vantage I GP-GP, LLC ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 Common Shares 2022-06-03 4 S 0 250000 12.2517 D 2344451 I See Footnote Common Shares 2022-06-03 4 S 0 438795 12.2517 D 1464875 I See Footnote Common Shares 2022-06-03 4 S 0 13199 12.2517 D 44065 I See Footnote Common Shares 2022-06-03 4 S 0 14611 12.2517 D 48776 I See Footnote Common Shares 2022-06-03 4 S 0 33395 12.2517 D 111484 I See Footnote Common Shares 2022-06-06 4 J 0 614315 0.00 D 850560 I See Footnote Common Shares 2022-06-06 4 J 0 132692 0.00 A 132692 I See Footnote Common Shares 2022-06-06 4 J 0 18478 0.00 D 25587 I See Footnote Common Shares 2022-06-06 4 J 0 3992 0.00 A 136684 I See Footnote Common Shares 2022-06-06 4 J 0 20454 0.00 D 28322 I See Footnote Common Shares 2022-06-06 4 J 0 4419 0.00 A 141103 I See Footnote Common Shares 2022-06-06 4 J 0 141103 0.00 D 0 I See Footnote Common Shares 2022-06-06 4 J 0 46753 0.00 D 64731 I See Footnote Common Shares 2022-06-06 4 J 0 10099 0.00 A 10099 I See Footnote Common Shares 2022-06-06 4 J 0 10099 0.00 D 0 I See Footnote Common Shares 231211 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners. Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners. Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners. Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners. Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. 2 of 2: Since there are 13 joint filers and EDGAR will not allow for entry of more than 10 joint filers, this Form 4 is being filed in conjunction with a Form 4 for Versant Ventures V, LLC, Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P., Versant Venture Capital V (Canada) LP, Versant Venture Capital V, L.P., Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P. and Versant Ventures VI GP-GP, LLC. /s/ Robin L. Praeger, Managing Director of Versant Vantage I GP-GP, LLC, general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, L.P. 2022-06-07 /s/ Robin L. Praeger, Managing Director of Versant Vantage I GP-GP, LLC, general partner of Versant Vantage I GP, L.P. 2022-06-07 /s/ Robin L. Praeger, Managing Director of Versant Vantage I GP-GP, LLC 2022-06-07